Bernd Mahlmann, Executive MBA is a Senior Business Development Executive enabling customer-centric transformation and driving growth in the international pharma and medical device industries for more than 15 years. At Ypsomed, Mr Mahlmann has also a particular focus on sustainability topics and facilitating pharma companies to complete their sustainability strategies with zero CO2 emission injection devices such as autoinjectors.

Jim Martineau is the Co-Founder / CEO of Nosis Biological Sciences. Mr Martineau co-founded Nosis after working for more than 15 years at the intersection of data science and healthcare innovation. Most recently, Mr Martineau was Head of Oncology Products at Natera (NASDAQ: NTRA) where he was responsible for the product roadmap, product definition, and strategic vision for Natera’s Oncology product portfolio. Prior to Natera, Mr Martineau spent four years with Flatiron Health (acquired by Roche in 2018 for $2 billion). Mr Martineau received his MBA in Health Care Management from The Wharton School at the University of Pennsylvania. He earned his MS in Computational & Mathematical Engineering from Stanford University and his BS in Engineering Physics from the Colorado School of Mines.

Jérôme Marzinski is a seasoned medtech leader, board member and investor in Life sciences, having held a variety of senior roles over a more than 25-year career, with significant experience in scaling and exiting venture capital projects, private equity-funded businesses in the sector, and having completed 15 M&A transactions and raised over €50m of growth capital.  

He is the CEO of OxSonics Therapeutics, a medtech spun off from the University of Oxford, which has developed SonoTran, an ultrasound-triggered drug delivery platform. Early efficacy and safety of the SonoTran was demonstrated in the first feasibility clinical trial run in Oxford, United Kingdom, on mCRC (metastatic colorectal cancer) patients.

Most recently Jérôme was the Interim Chief Executive Officer of Cimon Medical, overseeing the CE mark clearance for the Company’s lead product under new Medical Device Regulations. He is currently the Chairman of Cimon Medical. Prior to this, he spent three years as Chief Executive Officer at Visiometrics (Trade sale completed to a privately held ophthalmic company in the UK), spent six years in senior positions at ev3, and was Chief Operating Officer at Vexim. Jérôme has an MA in corporate financing and accounting from the University of Lille, and in 2012 completed the TRIUM Global Executive MBA, jointly issued by New York University Stern School of Business, London School of Economics and Political Science, and HEC Paris School of Management.

Bryan Mazlish co-founded Surf Bio in 2021 to commercialize a novel drug stabilization technology developed at Stanford University. He joined the life sciences industry a decade ago when a family diagnosis led him to co-found Bigfoot Biomedical, a diabetes-focused medical device company, in 2014. In 2021, FDA cleared Bigfoot’s first product, Bigfoot Unity. Mr Mazlish presently serves as a Board Member of Bigfoot after leaving his role as President in 2020. Prior to making the transition to life sciences, Mr Mazlish led a successful career in quantitative finance, where he managed trading desks at Citi and subsequently founded a fully automated trading company, Overlook Capital. Mr Mazlish graduated magna cum laude from Harvard College.

Matt McCawley has sixteen years of experience as a Mechanical Engineer, nine of which have been spent designing Pico-cylinders and Gas-powered drug and implant delivery medical device platforms. He currently holds nine patents, two related to the development of Pico-cylinders. He is a graduate of Cal Poly Pomona with a BS in Mechanical Engineering.

Jim McGough is co-founder and a Board Member at EdgeOne Medical Inc, a leading global Device Development and Testing Services firm for the Pharmaceutical Industry. He is also Managing Partner of EdgeOne Venture Partners. Additionally, he is an eclectic angel investor and board member or advisor in several HealthTech and Big Data/AI ventures. Earlier in his career Mr McGough held various Executive and Intrapreneurial leadership roles at Motorola, Audi, and Citigroup. Mr McGough likes to be on the leading edge of technological innovation—at Audi as Head of Marketing & eBusiness he championed and led the first integration of a smart-phone via Bluetooth so that a call could seamlessly transfer from your device to your vehicle. Mr McGough has a Master in International Management degree in International Finance from the Thunderbird Global School of Management and has a Bachelor of Arts degree in History from the University of California at Berkeley.

Alex McKeown joined Apellis Pharmaceuticals in September of 2020 in the Ophthalmology Research group, where he now leads the drug discovery and translational development at efforts. Alex earned his PhD in Vision Science from the University of Alabama at Birmingham in 2014 where he studied mechanisms of photoreceptor adaptation and degeneration. He then completed a Postdoc in adaptive optics ophthalmic imaging while pursuing an MBA. He has worked with various reading centers and in R&D with Heidelberg Engineering. In addition to his drug discovery/delivery efforts, he remains passionate about advancing disease understanding through ophthalmic imaging.

George Mihov PhD is a Principal Scientist at dsm-firmenich Biomedical who specializes in Biomaterials and Local Drug Delivery. He obtained his MSc in Chemistry at the Sofia University, Bulgaria, and earned his PhD in Polymer Chemistry and Pharmacy at the Max Planck Institute for Polymer Research in Mainz, Germany. George joined DSM in 2007 as a researcher in the field of medical biomaterials. Since then, George’s work has been mostly focused on degradable biomaterials, local drug delivery, and translation research, where he has over 20 patents and 30 peer-reviewed publications. Some of his notable achievements include his leadership in the technology implementation of TheraPEA biomaterial platform at dsm-firmenich Biomedical, extending the polymer family with tailor-made biomaterials for ophthalmology and contribution to the development of drug delivery concepts for cardio-vascular, pain-management, metabolic disorders, and ophthalmic therapeutic areas. The focus of his current research are long acting injectables and extended release of biologics.

Senda’s Chief Platform Officer, Stuart Milstein, has decades of experience in biotechnology, with a focus on establishing nucleic acid platform technologies such as siRNA, RNA editing and now, SendRNA™. Prior to Senda, Dr Milstein was VP, Platform Biology at Korro Bio, where he built and led high-throughput screening and platform biology functions and helped establish Korro’s ADAR-mediated RNA-editing platform. Previously, at Alnylam Pharmaceuticals, Dr Milstein helped to establish and then led the RNAi Lead Development group, contributing to the discovery and optimization of Onpattro®, the first approved RNAi therapeutic; Givlarri®, the first approved siRNA conjugate; and several other approved products for orphan and large indications.

Greg Moakes, an analytical chemist by training, received his PhD in Chemistry from Georgia Tech and later his MBA from Southern Methodist University in Dallas. He started his career working in the specialty materials business, spending time in global procurement, innovation leadership, sales leadership, and business development roles. Dr Moakes has over 15 years’ experience in launching products in the biomaterials, medical polymers, and drug-eluting implant fields. Dr Moakes currently leads commercial activities for the Sorrel wearable drug delivery device platform. He is passionate about partnering with pharmaceutical companies to ensure their combination products give the most intuitive, stress-free experience for patients.

Sukanya Murali is a Technical Services Manager at BD Medical-Pharmaceutical Systems. In this role, she serves as a key technical contact for some of BD’s top pharma customers in the vaccine and biologics therapeutic areas, supporting them in their drug-device combination product development and commercialization. In addition, she serves as a key scientific liaison in bringing innovative technologies and solutions to pharma’s drug delivery needs, such as deep cold storage, novel biologics and vaccines, traceability, and sustainability. Sukanya has several years of experience in the healthcare, medical devices and advanced materials industries and brings a diverse background in drug delivery, specialty polymers, connected devices, sustainability, and other related disciplines. Sukanya holds a PhD in Materials Science and Engineering and a Master’s in Chemical Engineering.